A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
received:
17
08
2020
accepted:
25
11
2020
pubmed:
22
12
2020
medline:
18
11
2021
entrez:
21
12
2020
Statut:
ppublish
Résumé
In children with cystic fibrosis (CF), the currently recommended amikacin dose ranges between 30 and 35 mg/kg/d; however, data supporting this dosing efficacy are lacking. In this article, the objectives were to develop a nonparametric pharmacokinetic population model for amikacin in children with CF and investigate the efficacy and toxicity at different dose rates for distinct minimum inhibitory concentration (MIC) clinical breakpoints using Monte Carlo simulations. Data from 94 children with CF (613 serum concentrations) from the Bordeaux University Hospital's CF-centre were analyzed. After determination of nonparametric pharmacokinetic population model parameters and associated influent covariates in Pmetrics, 1000 Monte Carlo simulations were performed for 7 different dose rates between 30 and 60 mg/kg/d, to predict the probability of obtaining peak serum amikacin ≥10 × MIC and trough level ≤2.5 mg/L, for MIC values between 1 and 16 mg/L. The median (min-max) age and weight were 10 (0.3-17) years and 29 (6-71) kg, respectively, with only 2 children younger than 1 year of age. Body weight and creatinine clearance significantly impacted the amikacin volume of distribution and clearance. The mean relative bias/root mean squared error between observed and individual predicted concentrations was -0.68%/8.1%. Monte Carlo simulations showed that for sensitive bacteria with MICs ≤ 4, 30 mg/kg/d was most appropriate for a 100% success rate; for bacteria with MICs ≥ 8 [eg, Pseudomonas aeruginosa (MICamikacin = 8)], a dose of at least 40 mg/kg/d allowed a high success probability (90%), with a trough level below 2.5 mg/L. For intermediate pathogens, a dose of at least 40 mg/kg/d can improve efficacy, with an acceptable calculated residual trough level in cases of normal or hyperfiltration. Because amikacin undergoes renal clearance, which is immature until 1 year of age, dosing recommendations for this age group may be markedly high, warranting cautious interpretation.
Sections du résumé
BACKGROUND
In children with cystic fibrosis (CF), the currently recommended amikacin dose ranges between 30 and 35 mg/kg/d; however, data supporting this dosing efficacy are lacking. In this article, the objectives were to develop a nonparametric pharmacokinetic population model for amikacin in children with CF and investigate the efficacy and toxicity at different dose rates for distinct minimum inhibitory concentration (MIC) clinical breakpoints using Monte Carlo simulations.
METHODS
Data from 94 children with CF (613 serum concentrations) from the Bordeaux University Hospital's CF-centre were analyzed. After determination of nonparametric pharmacokinetic population model parameters and associated influent covariates in Pmetrics, 1000 Monte Carlo simulations were performed for 7 different dose rates between 30 and 60 mg/kg/d, to predict the probability of obtaining peak serum amikacin ≥10 × MIC and trough level ≤2.5 mg/L, for MIC values between 1 and 16 mg/L.
RESULTS
The median (min-max) age and weight were 10 (0.3-17) years and 29 (6-71) kg, respectively, with only 2 children younger than 1 year of age. Body weight and creatinine clearance significantly impacted the amikacin volume of distribution and clearance. The mean relative bias/root mean squared error between observed and individual predicted concentrations was -0.68%/8.1%. Monte Carlo simulations showed that for sensitive bacteria with MICs ≤ 4, 30 mg/kg/d was most appropriate for a 100% success rate; for bacteria with MICs ≥ 8 [eg, Pseudomonas aeruginosa (MICamikacin = 8)], a dose of at least 40 mg/kg/d allowed a high success probability (90%), with a trough level below 2.5 mg/L.
CONCLUSIONS
For intermediate pathogens, a dose of at least 40 mg/kg/d can improve efficacy, with an acceptable calculated residual trough level in cases of normal or hyperfiltration. Because amikacin undergoes renal clearance, which is immature until 1 year of age, dosing recommendations for this age group may be markedly high, warranting cautious interpretation.
Identifiants
pubmed: 33346630
doi: 10.1097/FTD.0000000000000855
pii: 00007691-202108000-00009
doi:
Substances chimiques
Anti-Bacterial Agents
0
Amikacin
84319SGC3C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
499-504Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180:802–808.
Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005;293:581–588.
Bertino JS, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993;167:173–179.
Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43:1003–1012.
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93–99.
Mise au point sur le bon usage des aminosides administres par voie injectable. AFSSAPS. Available at: https://ansm.sante.fr/var/ansm_site/storage/original/application/f64613ed667c09bcb015026fa39e70a2.pdf. Accessed March, 2011.
Rey E, Tréluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet. 1998;35:313–329.
Prandota J. Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatr Infect Dis J. 1987;6:1111–1126.
Vic P, Ategbo S, Turck D, et al. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur J Pediatr. 1996;155:948–953.
Young DC, Zobell JT, Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol. 2013;48:1047–1061.
Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987;34:571–590.
Neely MN, van Guilder MG, Yamada WM, et al. Accurate detection of outliers and subpopulations with pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467–476.
Goutelle S, Bourguignon LC, Maire PH, et al. Population modeling and monte carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother. 2009;53:2974–2981.
Nolt VD, Pijut KD, Autry EB, et al. Amikacin target achievement in adult cystic fibrosis patients utilizing monte carlo simulation. Pediatr Pulmonol. 2019;54:33–39.
Caceres Guido P, Perez M, Halac A, et al. Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis. Pediatr Pulmonol. 2019;54:1801–1810.
Illamola SM, Huynh HQ, Liu X, et al. Population pharmacokinetics of amikacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2018;62:e00877–e00918.
Tréluyer JM, Merlé Y, Tonnelier S, et al. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother. 2002;46:1381–1387.
Belfayol L, Talon P, Eveillard M, et al. Pharmacokinetics of once-daily amikacin in pediatric patients. Clin Microbiol Infect. 1996;2:186–191.
EUCAST: Clinical Breakpoints and Dosing of Antibiotics. Available at: http://www.eucast.org/clinical_breakpoints/ . Accessed January 11, 2019.
Mustafa MH, Chalhoub H, Denis O, et al. Antimicrobial susceptibility of pseudomonas aeruginosa isolated from cystic fibrosis patients in northern europe. Antimicrob Agents Chemother. 2016;60:6735–6741.
Prickett MH, Hauser AR, McColley SA, et al. Aminoglycoside resistance of pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene. Thorax. 2017;72:40–47.
Raidt L, Idelevich EA, Dübbers A, et al. Increased prevalence and resistance of important pathogens recovered from respiratory specimens of cystic fibrosis patients during a decade. Pediatr Infect Dis J. 2015;34:700–705.
Mian AN, Schwartz GJ. Measurement and estimation of glomerular filtration rate in children. Adv Chronic Kidney Dis. 2017;24:348–356.
den Bakker E, Gemke RJ, Bökenkamp A. Endogenous markers for kidney function in children: a review. Crit Rev Clin Lab Sci. 2018;55:163–183.
Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.